Dr. Hare answers the question: 'Must I Repeat Ejection Fraction Tests?' — -- Question: Should the ejection fraction test be repeated at each visit to my doctor, or at all? Answer: The ejection ...
Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...
Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet VERQUVO was ...
The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...
Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. People with a history of heart failure — no matter the type — face more complications and death ...
Heart failure in which left ventricular ejection fraction recovers into the normal range has many unknowns. Andrew Perry, MD, discusses key management strategies with Jane Wilcox, MD, of Northwestern ...
The EMPEROR-Reduced trial previously showed that the sodium–glucose co-transporter 2 (SGLT2) inhibitor empagliflozin reduced the risk of cardiovascular death or hospitalisation for heart failure in ...
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback